Clinical efficacy of ceftazidime. Treatment of serious infection due to multiresistant Pseudomonas and other gram-negative bacteria

Publisher Website
Google Scholar
Abstract
Ceftazidime, a .beta.-lactamase stable cephalosporin, was administered to 57 patients. Substantial underlying disease was present in the majority of patients; 50% were in critical or poor condition. Ceftazidime inhibited all initial isolates of Enterobacteriaceae at .ltoreq. at 8 mg/l, regardless of resistance to other antibiotics, and the majority of P. aeruginosa at .ltoreq. 12 mg/l. The mean serum level after infusion of 1 g during 30 min was 62 mg/l. Overall clinical response was 84%; the bacteriological response was 72% excluding cystic fibrosis patients. No major adverse effects were encountered. Resistance developed in Pseudomonas from patients with cystic fibrosis and in Enterobacter from 2 other patients. Ceftazidime was an effective, safe therapy for serious infection due to multiply resistant Pseudomonas and other aerobic gram-negative bacilli including aminoglycoside-resistant Serratia and Klebsiella.

This publication has 3 references indexed in Scilit: